Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
700 participants
OBSERVATIONAL
2017-01-01
2019-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Discover In-Hospital Cardiac Arrest
NCT06207201
Neuroprotective Effect of Remote Ischemic Post-conditioning in Out-of-hospital Cardiac Arrest
NCT06473207
Post-Cardiotomy Extra-Corporeal Life Support Study
NCT03857217
Outcome of Cardiac Arrest Patients Following Guidelines Implementation Over the Years
NCT06608771
Free Iron and Out of Hospital Cardiac Arrest
NCT03491670
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypothesis: The hypothesis is that one-year survival after IHCA in Dutch hospitals is poor, consistent with international literature and our feasibility trial, and survival can be improved through selection, prevention and training.
Objective: The main objective of this study is to assess the one-year survival of patients after CPR for in-hospital cardiac arrest. The secondary objectives are to assess quality of life and functional status after successful CPR. Furthermore the investigators aim to assess if there are patient-related predicting factors for these outcome measures and to assess whether outcomes are influenced by hospital-related factors (i.e. CPR training and treatment options).
Study design: The current study has a prospective, observational design, with a 12-month follow-up. Patients will be included from January 1st 2017. Patient data collection will take place at four time points: T0= directly post-CPR, T1= at hospital discharge or at in-hospital death, T2= 3 months after CPR, T3= 12 months after CPR. Clinical data will be collected at all time points. Quality of life data will be collected at T2 and T3 by means of validated questionnaires. We will assess functional status through questionnaires and link these to pre-existing and acquired comorbidities (e.g. stroke). General hospital data and data concerning the level of CPR-training will be ascertained at four moments during the first year of patient inclusion.
Study population: An estimated six hundred patients of 18 years or older who will receive CPR for cardiac arrest in the participating hospitals. This will include all cases of in-hospital cardiac arrest, also including Operation Room (OR), Intensive/Coronary Care Unit (ICU/CCU) and Emergency Department (ER). Patients in whom CPR was started before arrival in hospital will be excluded.
Expected results: The main study endpoints are one-year survival and quality of life. Secondary endpoints are direct survival and survival to discharge. The first preliminary results are expected in the first quarter of 2018. After conclusion of this project the investigators of this project aim to develop recommendations that will improve survival after IHCA.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Receiving cardiopulmonary resuscitation, as defined by starting manual chest compressions, for a circulatory arrest occuring in-hospital.
* In hospital is defined as all hospital wards, departments, outpatient clinics, and hallways.
Exclusion Criteria
* Purposely induced cardiac arrest (e.g. cardiac surgery)
* Purposely induced arrhythmias (e.g. electrophysiological treatment)
* Refusal to participate
* Primary out-of-hospital cardiac arrest with re-arrest \<24h after hospital admission.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Erasmus Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marc Schluep
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Jan Stolker, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Erasmus Medical Center
Marc Schluep, MD
Role: PRINCIPAL_INVESTIGATOR
Erasmus Medical Center
Sanne Hoeks, PhD
Role: STUDY_CHAIR
Erasmus Medical Center
Henrik Endeman, MD PhD
Role: STUDY_CHAIR
OLVG
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rijnstate Ziekenhuis
Arnhem, Gelderland, Netherlands
OLVG
Amsterdam, North Holland, Netherlands
Deventer Ziekenhuis
Deventer, Overijssel, Netherlands
Medisch Spectrum Twente
Enschede, Overijssel, Netherlands
Isala klinieken
Zwolle, Overijssel, Netherlands
Amphia Ziekenhuis
Breda, South Holland, Netherlands
Reinier de Graaf Gasthuis
Delft, South Holland, Netherlands
Albert Schweitzer Ziekenhuis
Dordrecht, South Holland, Netherlands
Sint Franciscus Vlietland Groep
Rotterdam, South Holland, Netherlands
Maasstad Ziekenhuis
Rotterdam, South Holland, Netherlands
Haaglanden Medisch Centrum
The Hague, South Holland, Netherlands
ZorgSaam Zeeuws-Vlaanderen
Terneuzen, Zeeland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NTR6145
Identifier Type: OTHER
Identifier Source: secondary_id
MEC-2016-563
Identifier Type: OTHER
Identifier Source: secondary_id
ABR55661.078.16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.